Lithospermoside
Based on 1 Customer Validation
Lithospermoside (Griffonin) is an orally active Na+/K+-ATPase inhibitor and hypoglycemic agent. Lithospermoside increases intracellular sodium levels in normal and sickle red blood cells. Lithospermoside reduces fasting blood glucose levels, improves glucose tolerance, and prevents weight loss in diabetic mice. Lithospermoside can be used in the research of sickle cell disease and diabetes.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.48%
- CAS 番号: 63492-69-3
- 分子式: C14H19NO8
- 分子量:329.30
-
保管条件:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
生物活性
製品説明
体外実験
Lithospermoside (0.5-1.0 mmol/l; 8 h) at 1.0 mmol/l significantly increases intracellular sodium content in erythrocytes from normal human subjects (P < 0.05), while 0.5 mmol/l has little effect over an 8-hour incubation[1].
Lithospermoside (0.5-1.0 mmol/l; 8 h) at 0.5 mmol/l and 1.0 mmol/l significantly increases intracellular sodium content in erythrocytes from human sickle cell patients (P < 0.05 to P < 0.001), with a larger effect observed at 1.0 mmol/l and a greater response in sickle cell erythrocytes compared to normal erythrocytes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Swiss mice (male, 60 days old, 40-50 g, streptozotocin-induced diabetic)[2]
-
Dosage:1, 5, 10 and 20 mg/kg
-
Administration:p.o.; daily; 14 days
-
Result:Showed a significant increase in body weight compared to diabetic control after 7 and 14 days at 10 and 20 mg/kg.
Maintained body weight, with a significant difference compared to diabetic control after 14 days at 1 and 5 mg/kg.
Reduced fasting glycemia by 34% compared to diabetic control over 14 days at 10 and 20 mg/kg.
Showed a significant difference in glycemia compared to diabetic control after 14 days at 1 and 5 mg/kg.
Decreased glucose levels from 30 minutes post-glucose load, with significantly lower AUC compared to diabetic control, similar to metformin-treated group at 10 mg/kg.
化学情報
-
CAS 番号 63492-69-3
-
性状 Solid
-
分子量 329.30
-
分子式 C14H19NO8
-
Color White to off-white
-
SMILES
O[C@@H]1[C@@](/C(C=C[C@H]1O)=C\C#N)([H])O[C@@H]([C@@H]([C@@H](O)[C@@H]2O)O)O[C@@H]2CO
-
別名
リトスペルモシド; Griffonin
-
Structure Classification
-
Initial Source
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
溶剤 & 溶解度
体外:
H2O : 31.25 mg/mL (94.90 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (279 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Larmie ET, et al. The in vitro effects of griffonin and ouabain on erythrocyte sodium content obtained from normal subjects and sickle cell patients. Planta medica. 1991 Apr;57(2):116-8. [Content Brief]
[2]. Saldanha LL, et al. Hypoglycemic active principles from the leaves of Bauhinia holophylla: Comprehensive phytochemical characterization and in vivo activity profile. PloS one. 2021;16(9):e0258016. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 3.0367 mL | 15.1837 mL | 30.3674 mL | 75.9186 mL |
| 5 mM | 0.6073 mL | 3.0367 mL | 6.0735 mL | 15.1837 mL | |
| 10 mM | 0.3037 mL | 1.5184 mL | 3.0367 mL | 7.5919 mL | |
| 15 mM | 0.2024 mL | 1.0122 mL | 2.0245 mL | 5.0612 mL | |
| 20 mM | 0.1518 mL | 0.7592 mL | 1.5184 mL | 3.7959 mL | |
| 25 mM | 0.1215 mL | 0.6073 mL | 1.2147 mL | 3.0367 mL | |
| 30 mM | 0.1012 mL | 0.5061 mL | 1.0122 mL | 2.5306 mL | |
| 40 mM | 0.0759 mL | 0.3796 mL | 0.7592 mL | 1.8980 mL | |
| 50 mM | 0.0607 mL | 0.3037 mL | 0.6073 mL | 1.5184 mL | |
| 60 mM | 0.0506 mL | 0.2531 mL | 0.5061 mL | 1.2653 mL | |
| 80 mM | 0.0380 mL | 0.1898 mL | 0.3796 mL | 0.9490 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.